TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Omega Diagnostics ( (GB:CNSL) ) has provided an update.
Cambridge Nutritional Sciences plc announced that Carolyn Rand, Non-Executive Chair, and Jeremy Millard, Non-Executive Director, have acquired additional shares in the company. Rand purchased 150,000 shares at an average price of 2.32 pence, while Millard acquired 168,776 shares at 2.37 pence each. These transactions reflect a vote of confidence in the company’s future prospects by its leadership, potentially impacting stakeholder perceptions and market positioning.
The most recent analyst rating on (GB:CNSL) stock is a Hold with a £3.00 price target. To see the full list of analyst forecasts on Omega Diagnostics stock, see the GB:CNSL Stock Forecast page.
Spark’s Take on GB:CNSL Stock
According to Spark, TipRanks’ AI Analyst, GB:CNSL is a Neutral.
Omega Diagnostics’ overall stock score is primarily influenced by its mixed financial performance and bearish technical indicators. While the company shows profitability and financial stability, significant cash flow challenges and declining revenue are concerns. The technical analysis indicates a strong downtrend, further impacting the score. The stock appears undervalued based on its P/E ratio, providing some upside potential.
To see Spark’s full report on GB:CNSL stock, click here.
More about Omega Diagnostics
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading health and nutrition products.
Average Trading Volume: 301,410
Technical Sentiment Signal: Sell
Current Market Cap: £5.35M
See more insights into CNSL stock on TipRanks’ Stock Analysis page.